Clindamycin
(generic name; brand names include Clindamax, Dalacin, etc.)
---
1. What Is It?
Clindamycin is a lincosamide antibiotic. It was first isolated from Streptomyces lincolnensis and has been used clinically since the 1970s. It’s available in several formulations:
| Form | Typical Use |
|------|-------------|
| Oral capsules/tablets | Mild‑to‑moderate infections, dental abscesses, acne, etc. |
| Oral suspension | Children, or when tablets are impractical. |
| Topical cream/gel | Acne, mild skin infections. |
| Intravenous (IV) infusion | Severe infections, sepsis, surgical prophylaxis. |
| Injectable (intramuscular) | Emergency situations where IV access isn’t available. |
---
2. Mechanism of Action
- Inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome.
- This blocks the translocation step of peptide elongation, effectively “freezing” the ribosome in place.
- It is bacteriostatic against most organisms but becomes bactericidal against many anaerobes and Gram‑positive cocci at higher concentrations.
---
3. Spectrum of Activity
| Category | Typical Bacteria |
|----------|------------------|
| Gram‑positive | Streptococcus spp., Staphylococcus aureus (including many MRSA strains), Enterococcus faecalis (usually susceptible). |
| Anaerobic | Bacteroides fragilis, Clostridium spp., Peptostreptococcus spp. |
| Gram‑negative | Limited activity; mainly effective against Pseudomonas aeruginosa when combined with other agents. |
Key point: Clindamycin is a first‑line choice for anaerobic infections and skin/soft‑tissue infections, especially when MRSA is a concern.
---
4. Common Indications
| Infection Type | Typical Dosage (Adults) | Notes |
|----------------|------------------------|-------|
| Skin/soft‑tissue (cellulitis, abscess) | 300–450 mg PO q6h (or 600 mg IV q8h) | Often used alone for mild cases; add β‑lactam if polymicrobial. |
| Bone/Joint | 600 mg PO q8h | IV preferred for severe osteomyelitis. |
| Intra‑abdominal (peritonitis, abscess) | 600 mg IV q8h | Usually part of a multi‑drug regimen. |
| Dental abscess | 300 mg PO q6h for 10–14 days | Often combined with metronidazole or amoxicillin. |
| Acne (topical) | 0.1–1 % gel/cream | Usually a short course (2–4 weeks). |
| Vaginal candidiasis (rare) | 50 mg PO q6h | Not a first‑line therapy but used when azoles fail. |
Dosing adjustments are needed for renal or hepatic impairment (see below).
---
5. Pharmacokinetics (Adults)
- Absorption: ~90% orally; peak serum concentration ~1 hour after dosing.
- Distribution: Good tissue penetration; high concentration in skin, bone, liver, and CSF (especially with IV).
- Metabolism: Mostly via conjugation in the liver; some first‑pass metabolism.
- Excretion: Primarily via feces (biliary); ~15–20% in urine.
- Half‑life: ~2–3 hours (oral); ~3–4 hours (IV).
---
6. Contraindications & Precautions
| Category | Key Points |
|----------|------------|
| Allergies | Avoid in patients with known hypersensitivity to clindamycin or other lincosamides. |
| C. difficile–associated diarrhea | High risk; avoid if the patient has a history of recurrent C. difficile infection. |
| Pregnancy | Category B (animal data show no risk; no controlled human data). Use only if benefits outweigh potential risks. |
| Breastfeeding | Low levels in milk; generally considered compatible. |
| Renal impairment | Dose may need adjustment; monitor for accumulation, especially in CKD stage 4–5. |
| Hepatic impairment | Generally safe; monitor liver function tests. |
| Severe anemia or neutropenia | Rarely used as a primary therapy in such patients. |
Special caution: In patients with a history of Clostridioides difficile infection, consider alternative agents or use with extreme caution.
---
7. Common Adverse Effects
| Category | Examples |
|----------|----------|
| Gastrointestinal | Nausea, vomiting, abdominal pain, diarrhea (including pseudo‑diarrhea). |
| Dermatologic | Rash, pruritus, Stevens–Johnson syndrome (rare). |
| Metabolic | Hyperglycemia (rare). |
| Hematologic | Rare anemia, leukopenia. |
| Others | Rare cases of hepatotoxicity, hypokalemia, or seizures (very uncommon). |
Most serious: Clostridioides difficile‑associated colitis – presents with watery diarrhea, abdominal pain, fever, and often a “pseudomembranous” picture on sigmoidoscopy.
---
8. Drug Interactions
| Drug/Category | Interaction |
|---------------|-------------|
| Metronidazole | Synergistic activity; no major PK interaction. |
| Amoxicillin/clavulanate | Often combined for polymicrobial coverage. |
| β‑lactams | Additive effect against Gram‑positive bacteria. |
| Non‑steroidal anti‑inflammatory drugs (NSAIDs) | No significant interaction. |
| Antacids | Reduce absorption slightly; give 1–2 hours apart. |
| Warfarin | No direct interaction, but antibiotic use can alter gut flora and vitamin K levels; monitor INR. |
| Corticosteroids | May increase risk of C. difficile colitis. |
| Other antibiotics | Combination therapy may increase the risk of C. difficile; use with caution. |
---
9. Resistance & Considerations
- Clindamycin resistance is primarily mediated by methylation of the 23S rRNA (erm genes).
- Resistance rates vary by region and infection type; check local antibiograms.
- Use clindamycin susceptibility testing for serious infections (e.g., MRSA, Enterococcus).
- Vancomycin‑resistant enterococci (VRE) are usually susceptible to clindamycin, but confirm in vitro.
---
10. Patient Counseling Checklist
1. Take as prescribed – complete the full course even if symptoms improve.
2. Take with food – helps reduce GI upset.
3. Avoid alcohol – can worsen GI side effects.
4. Watch for diarrhea – especially if it’s watery or bloody; report promptly.
5. Notify your clinician if you develop rash, itching, or signs of an allergic reaction.
6. Inform all healthcare providers before starting other antibiotics or supplements.
7. Maintain good hygiene – particularly in wound care or post‑surgical settings.
8. Follow up – repeat cultures or imaging if symptoms persist.
---
11. Quick Reference: Adult Dosing (Typical)
| Situation | Oral | IV |
|-----------|------|-----|
| Mild skin infection | 300–450 mg q6h | 600 mg q8h |
| Severe infection (e.g., osteomyelitis) | 600 mg q8h | 600 mg q8h |
| Children (weight‑based) | 10–15 mg/kg q6–8h | 10 mg/kg q8h |
| Renal impairment | Decrease dose or interval | Decrease dose or interval |
| Pregnancy | Use only if needed | Use only if benefits outweigh risks |
Always confirm dosing with the prescribing clinician or pharmacy.
---
12. Bottom Line
Clindamycin is a versatile, effective antibiotic particularly suited for:
- Anaerobic infections (e.g., intra‑abdominal abscesses, pelvic infections).
- **Skin